Abstract
To describe major depressive disorder (MDD) patients initiating antidepressants (ADs) treatment in terms of healthcare resources utilization (HRU) and sick leave (SL) experience by therapeutic approach This was a real-world evidence retrospective study using general practitioners (GPs) and specialists (psychiatrists and neurologists) data from IQVIA German Disease Analyzer and Spanish Longitudinal Patient Database. 19-64 years-old MDD patients initiating treatment with ADs during ‘July 2016 - June 2018’ were selected and followed-up for a 12-month period. Patients were classified depending on the therapeutic approach as: 1) AD monotherapy (ADMONO - no ADs molecules different from the one received at treatment start during follow-up) or 2) AD combination/switch/add-on patients (ADCOM - more than one AD molecule prescribed at treatment start and/or AD molecules different from the initial one during follow-up). HRU (GPs and specialists visits and co-prescriptions) and SL registrations (due to any cause, due to psychiatric/neurologic reasons, and MDD-related respectively for German GPs, German specialists, and Spanish panels) during follow-up were analysed by group of AD therapeutic approach 8,891, 1,685, and 1,817 patients were respectively selected from German GPs, German specialists, and Spanish GPs/specialists panels. ADMONO approach was the most frequent for all the three cohorts. ADCOM patients had more visits requests and concomitant drugs prescriptions compared to ADMONO ones. Moreover, SL registrations were more frequently recorded for ADCOM patients. In particular, patients with 31+ days of SL were 44% and 28% respectively for ADCOM and ADMONO in the German GPs cohort, 23% and 12% respectively for ADCOM and ADMONO in the German specialists cohort, and 16% and 4% respectively for ADCOM and ADMONO in the Spanish cohort Results from this study reflect different perspectives on MDD patients management and consistently showed that ADMONO is associated with lower HRU and SL recording in patients with MDD.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
